GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomea Fusion Inc (NAS:BMEA) » Definitions » Equity-to-Asset

Biomea Fusion (Biomea Fusion) Equity-to-Asset : 0.80 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biomea Fusion Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biomea Fusion's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $135.31 Mil. Biomea Fusion's Total Assets for the quarter that ended in Mar. 2024 was $168.49 Mil.

The historical rank and industry rank for Biomea Fusion's Equity-to-Asset or its related term are showing as below:

BMEA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.08   Med: 0.89   Max: 0.96
Current: 0.8

During the past 5 years, the highest Equity to Asset Ratio of Biomea Fusion was 0.96. The lowest was -0.08. And the median was 0.89.

BMEA's Equity-to-Asset is ranked better than
67.48% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs BMEA: 0.80

Biomea Fusion Equity-to-Asset Historical Data

The historical data trend for Biomea Fusion's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomea Fusion Equity-to-Asset Chart

Biomea Fusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-0.08 0.08 0.96 0.84 0.85

Biomea Fusion Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.90 0.89 0.85 0.80

Competitive Comparison of Biomea Fusion's Equity-to-Asset

For the Biotechnology subindustry, Biomea Fusion's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomea Fusion's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's Equity-to-Asset falls into.



Biomea Fusion Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Biomea Fusion's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=169.237/199.927
=

Biomea Fusion's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=135.314/168.494
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomea Fusion  (NAS:BMEA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Biomea Fusion Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Biomea Fusion's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomea Fusion (Biomea Fusion) Business Description

Traded in Other Exchanges
N/A
Address
900 Middlefield Road, 4th Floor, Redwood City, CA, USA, 94063
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Executives
Juan Pablo Frias officer: Chief Medical Officer 900 MIDDLEFIELD ROAD, 4TH FLOOR, C/O BIOMEA FUSION, INC., REDWOOD CITY CA 94063
A2a Pharmaceuticals, Inc. 10 percent owner 59 5TH AVE, NEW YORK NY 10003
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen director, 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Hitchcock Michael J.m. director C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Franco Valle officer: Chief Financial Officer 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Elizabeth Faust director C/O BIOMEA FUSION, INC., 900 MIDDLEFIELD RD., 4TH FL, REDWOOD CITY CA 94063
Sumita Ray director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Sotirios Stergiopoulos director C/O BIOMEA FUSION, INC., 726 MAIN STREET, REDWOOD CITY CA 94063
Rainer M Erdtmann director, 10 percent owner, officer: President and COO 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Thomas Andrew Butler director, 10 percent owner, officer: CEO 726 MAIN STREET, REDWOOD CITY CA 94065
Eric Aguiar director 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Biomea Health, Llc 10 percent owner 726 MAIN STREET, REDWOOD CITY CA 94063

Biomea Fusion (Biomea Fusion) Headlines

From GuruFocus